Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Table 3 Clinical and immunological outcome

Blood-derived DC treated patient^~	Measurable disease sites at baseline^a	Radiological progression-free survival (mo)^b	Overall survival (mo)	Dm^c SKILs^e	IFN-γ^c SKILs^e	Number of vaccinations
mDC-01	Bone	23.6	36.1^c	+	+	9
mDC-02	–	24.3^c	34.8^c	+	+	9
mDC-03	–	24.8^c	34.8^c	+	–	9
mDC-04	LN, bone	3.4	28.0	+	–	3
mDC-05	LN	12.0	30.2^c	+	+	6
mDC-06	Bone	3.4	23.3	–	+	3
mDC-07	LN, bone	3.4	17.1	+	–	3
pDC-01	LN	18.8	36.8^c	+	+	9
pDC-02	Bone	6.4	24.9	–	+	6
pDC-03	LN, bone	3.4	20.0	–	–	3
pDC-04	LN	18.9	27.6^c	+	–	9
pDC-05	Bone	6.1	27.6^c	–	+	6
pDC-06	LN	23.9^c	37.8^c	+	–	9
pDC-07	LN, bone	10.7^d	10.7	+	–	6
combiDC-01	Bone	4.2	41.2^c	–	–	3
combiDC-02	Bone	3.2	21.7	+	–	3
combiDC-03	–	3.7	20.4	+	–	3
combiDC-04	Bone	9.5	27.2^c	+	–	6
combiDC-05	Bone	3.4	26.7^c	–	–	3
combiDC-06	LN, bone	9.7	25.6^c	+	–	6
combiDC-07	LN, bone	12.0	24.4^c	+	+	9

DC dendritic cells, Dm dextramer, LN lymph nodes, mo months, SKILs skin-infiltrating lymphocytes
^ameasurable disease sites were determined on advanced imaging with contrast-enhanced ⁶⁸Ga-prostate-specific membrane antigen (PSMA) PET/CT scans, for RECIST 1.1 and ferumoxtran-10-enhanced MRIs and MRI bones for PCWG2 criteria
^bradiological responses were assessed on contrast-enhanced ⁶⁸Ga-PSMA PET/CT scans, ferumoxtran-10-enhanced MRIs and MRI lymph nodes for RECIST 1.1 and MRI bones for PCWG2 criteria. In case of progressive disease according to RECIST 1.1 and/or PCWG2 criteria a confirmatory MRI lymph nodes and bones was performed 6–8 weeks later. The date used for calculation of progression-free survival was the first date at which progression criteria were met (the date of unconfirmed progression of disease)
^cprogression-free survival or overall survival endpoint not reached in this patient
^dpatient had stable disease according to RECIST 1.1 and PCWG2 criteria. At 10.7 months after apheresis patient deceased due to a ruptured type A acute aortic dissection
^etetramer- or dextramer-positivity (dm⁺) or IFN-γ-positivity of SKILs if at least for one epitope CD8⁺ dm⁺ or IFN-γ⁺ T cells were detected